# Ranger™ and Ranger™ SL (OTW) DCB) in China

Study · id `cardio:ct-nct02944071` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02944071](<https://clinicaltrials.gov/study/NCT02944071>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02944071

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 123 participants.

## Technical summary

Registry record NCT02944071. Allocation not applicable; no masking; primary purpose treatment. Start 2016-11-24 (actual); primary completion 2020-12-22 (actual). Results posted on 2022-03-10.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 123 participants (enrolled count; ClinicalTrials.gov record NCT02944071, source copy `cardio:ctgov-nct02944071-2025-10-27`, retrieved 2026-10-31)
- Started: 2016-11-24 (actual) (ClinicalTrials.gov record NCT02944071, source copy `cardio:ctgov-nct02944071-2025-10-27`, retrieved 2026-10-31)
- Primary completion: 2020-12-22 (actual) (ClinicalTrials.gov record NCT02944071, source copy `cardio:ctgov-nct02944071-2025-10-27`, retrieved 2026-10-31)
- Completion: 2020-12-22 (actual) (ClinicalTrials.gov record NCT02944071, source copy `cardio:ctgov-nct02944071-2025-10-27`, retrieved 2026-10-31)
- Results first posted: 2022-03-10 (ClinicalTrials.gov record NCT02944071, source copy `cardio:ctgov-nct02944071-2025-10-27`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT02944071, source copy `cardio:ctgov-nct02944071-2025-10-27`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02944071-2025-10-27`, retrieved 2026-10-31)

## The registry's words

- Brief title: Ranger™ and Ranger™ SL (OTW) DCB) in China
- Condition: Femoropopliteal Artery Lesions
- Intervention (Device): Boston Scientific Ranger™ and Ranger™ SL Paclitaxel-Coated PTA Balloon Catheter
- Lead sponsor: Boston Scientific Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry lists this organization as the lead sponsor: Boston Scientific (`cardio:boston-scientific`)

## Provenance

Content hash: 19119fd8d5fd1904ba70ba2b4b307544af93e3d9e965ed9fe4d7a39479d6a262
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
